PT103884A - Composições de libertação prolongada e métodos para a sua preparação - Google Patents

Composições de libertação prolongada e métodos para a sua preparação Download PDF

Info

Publication number
PT103884A
PT103884A PT103884A PT10388407A PT103884A PT 103884 A PT103884 A PT 103884A PT 103884 A PT103884 A PT 103884A PT 10388407 A PT10388407 A PT 10388407A PT 103884 A PT103884 A PT 103884A
Authority
PT
Portugal
Prior art keywords
formulations
preparation
methods
prolonged release
release compositions
Prior art date
Application number
PT103884A
Other languages
English (en)
Inventor
Daniel Brown
Donna Caster
Sandra Hopkins
Jennifer Llewelyn
Lisa Martin
Robert Timko
Husheng Yang
Brian Clark
Elizabeth Meehan
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/561,306 external-priority patent/US20070185080A1/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PT103884A publication Critical patent/PT103884A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

FORMULAÇÕES DE LIBERTAÇÃO PROLONGADA DE QUETIAPINA E OS SEUS SAIS FARMACÊUTICOS E OS MÉTODOS DE PREPARAÇÃO DAS FORMULAÇÕES, PODEM INCLUIR A UTILIZAÇÃO DE POLÍMEROS SELECCIONADOS PELAS SUAS CARACTERÍSTICAS FÍSICAS E QUÍMICAS. AS FORMULAÇÕES PODEM INCLUIR POLÍMEROS SELECCIONADOS PARA FAZER COM QUE AS FORMAS DE DOSAGEM SÓLIDAS DAS FORMULAÇÕES FIQUEM CONFORME CRITÉRIOS PRÉ-SELECCIONADOS DE LIBERTAÇÃO DE QUETIAPINA. AS FORMULAÇÕES PODEM INCLUIR MATERIAIS NÃO POLIMÉRICOS QUE POSSAM AFECTAR A LIBERTAÇÃO DE QUETIAPINA.
PT103884A 2006-11-17 2007-11-14 Composições de libertação prolongada e métodos para a sua preparação PT103884A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/561,306 US20070185080A1 (en) 2005-11-18 2006-11-17 Pharmaceutical Compositions
US93064307P 2007-05-16 2007-05-16

Publications (1)

Publication Number Publication Date
PT103884A true PT103884A (pt) 2008-05-19

Family

ID=40028121

Family Applications (1)

Application Number Title Priority Date Filing Date
PT103884A PT103884A (pt) 2006-11-17 2007-11-14 Composições de libertação prolongada e métodos para a sua preparação

Country Status (12)

Country Link
US (2) US20080287418A1 (pt)
EP (1) EP2160183A4 (pt)
JP (1) JP2010526874A (pt)
CN (1) CN101754752A (pt)
BE (1) BE1018260A3 (pt)
CA (1) CA2610652A1 (pt)
DE (1) DE102007054788A1 (pt)
FR (1) FR2908657A1 (pt)
NO (1) NO20093540L (pt)
PT (1) PT103884A (pt)
SE (1) SE0702522L (pt)
WO (1) WO2008060228A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173637B2 (en) * 2008-07-24 2012-05-08 Handa Pharmaceuticals, Llc Stabilized atypical antipsychotic formulation
DE102008046650A1 (de) 2008-09-10 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Quetiapin enthaltende Retardtablette
WO2010089259A2 (en) * 2009-02-04 2010-08-12 Woerwag R&D Gmbh Sustained release composition containing quetiapine
WO2011132008A2 (en) 2010-04-22 2011-10-27 EGIS Gyűgyszergyár Nyilvánosan Múködő Részvény társaság Controlled release pharmaceutical composition
WO2011154118A1 (en) 2010-06-07 2011-12-15 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Quetiapine prolonged-release tablets
TR201008261A1 (tr) 2010-10-08 2012-04-24 Sanovel İlaç San. Ve Ti̇c. A.Ş. Kontrollü salım gerçekleştiren ketiapin formülasyonları
DE102011115690A1 (de) 2011-10-11 2013-04-11 Acino Pharma Ag Quetiapin enthaltende Formulierungen
MA38576B2 (fr) * 2013-11-26 2020-02-28 Murray And Poole Enterprises Ltd Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières
CN104586805A (zh) * 2014-07-08 2015-05-06 上海中西三维药业有限公司 富马酸喹硫平缓释片剂及其制备方法
CN113331425B (zh) * 2021-06-07 2022-06-14 中国农业大学 一种软骨多糖缓释剂及其制备方法与应用
AR131061A1 (es) 2022-11-15 2025-02-12 Basf Agrochemical Products Bv Formulaciones de concentrado en suspensión acuosa de activos agroquímicos
WO2025035066A1 (en) * 2023-08-10 2025-02-13 Biohaven Therapeutics Ltd. Extended-release formulations of kv7.2/7.3 potassium channel activators

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839319A (en) * 1973-01-26 1974-10-01 Dow Chemical Co Hydroxypropyl methylcellulose ethers and method of preparation
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
GB8705574D0 (en) 1987-03-10 1987-04-15 Ici Plc Preparation of thiazepine compound
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
GB9611328D0 (en) * 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
US5948440A (en) * 1997-12-17 1999-09-07 Ranbaxy Laboratories Limited Modified release matrix formulation of cefaclor and cephalexin
JP4637338B2 (ja) * 2000-09-22 2011-02-23 大塚製薬株式会社 シロスタゾール有核錠
US20020160991A1 (en) * 2000-12-04 2002-10-31 Liming Shao Orally-bioavailable formulations of fentanyl and congeners thereof
US7544681B2 (en) * 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
US20040006072A1 (en) * 2002-06-25 2004-01-08 Franz Robert M. Sustained-release alprazolam composition
DE602004024798D1 (de) * 2003-09-23 2010-02-04 Fermion Oy Herstellung von quetiapin
US20050158383A1 (en) * 2003-10-21 2005-07-21 Garth Boehm Quetiapine formulations
CA2549225A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride
US20060188444A1 (en) * 2005-02-23 2006-08-24 Otsuka Pharmaceutical Co., Ltd. Method for monitoring patient or subject compliance with medical prescriptions, and formulation for use in the method

Also Published As

Publication number Publication date
BE1018260A3 (fr) 2010-08-03
NO20093540L (no) 2009-12-16
EP2160183A4 (en) 2013-02-13
FR2908657A1 (fr) 2008-05-23
WO2008060228A1 (en) 2008-05-22
CN101754752A (zh) 2010-06-23
CA2610652A1 (en) 2008-05-17
SE0702522L (sv) 2008-05-18
US20110319383A1 (en) 2011-12-29
US20080287418A1 (en) 2008-11-20
JP2010526874A (ja) 2010-08-05
EP2160183A1 (en) 2010-03-10
DE102007054788A1 (de) 2008-07-03

Similar Documents

Publication Publication Date Title
PT103884A (pt) Composições de libertação prolongada e métodos para a sua preparação
CY2024007I1 (el) Γλυκοπυρανοζυλο-υποκατεστημενα παραγωγα βενζονιτριλιου, φαρμακευτικες συνθεσεις που περιεχουν τετοιες ενωσεις, η χρηση τους και μεθοδοι παρασκευης τους
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
UY30319A1 (es) Formulaciones de inhibidores de dpp iv
BR112015014372A8 (pt) inibidores de autotaxina, seus usos, e composição e combinação farmacêuticas".
MA32200B1 (fr) Nouvelles formulations,comprimes comprenant de telles formulations, leur utilisation et leur procede de preparation
CL2007002607A1 (es) Compuestos derivados de aril-sulfonamida o piridin-sulfonamida; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento de una enfermedad o trastorno mediado por las interacciones de los linfocitos, tales como artritis reumatoide,
EA201101190A1 (ru) Фармацевтическая композиция, включающая линаглиптин и необязательно ингибитор sglt2, и ее применение
BRPI0814666A2 (pt) composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida
UY31570A1 (es) Derivados de oxadiazol agonistas del receptor s1p1. composiciones farmacéuticas que lo comprenden y procedimientos de preparacion de los mismos
CL2004000303A1 (es) Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
BR112014012878A8 (pt) composto, uso de um composto, composição farmacêutica e processos de fabricação de um composto
CL2008000403A1 (es) Compuestos derivados de pentafluorotiobenzamido-acetonitrilo; composicion farmaceutica; y uso para tratar una infestacion por parasitos.
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
CL2007003423A1 (es) Compuestos derivados de pirimidinas sustituidas; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de artritis reumatoidea, aterosclerosis, entre otras enfermeda
BRPI0816881A2 (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
NI201000189A (es) Formulación de medicamento sólido con liberación retardadas.
BRPI0710232B8 (pt) composto antagonista do receptor de il-8, composição farmacêutica que compreende o dito composto e uso do mesmo para o tratamento de uma doença mediada por quimiocina
BRPI0922233A2 (pt) compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
DOP2010000299A (es) Uso de dronedarona para la preparacion de un medicamento para uso en la prevencion de la hospitalizacion cardiovascular o de la mortalidad
BRPI0816255A2 (pt) Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável
CR8717A (es) Nuevos compuestos
CL2007001917A1 (es) Compuestos derivados de azaindol espirociclicos; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del dolor, condiciones de panico, depresion, mal de alzheimer, migrana, entre otras.
CO6640305A2 (es) Elaboración de gránulos sin activos y tabletas que comprenden los mismos
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 20080228

FC3A Refusal

Effective date: 20090227